Consolidated Balance Sheets (USD $)	Dec. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 6,168,754	$ 7,700,156
Restricted cash	231,838	706,802
Accounts receivable, net	1,986,663	1,917,699
Inventories, net	1,414,600	1,187,895
Note receivable-related parties		239,476
Loans to customer and supplier	2,892,868	2,513,460
Other receivables	483,884	53,936
Prepayments	9,029,524	3,633,674
Other current assets	132,746	914,594
Deferred tax assets	27,042	46,042
Total current assets	22,367,919	18,913,734
Property, plant and equipment, net	4,813,232	4,771,299
Construction in progress	295,248	35,878
Intangible assets, net	1,238,025	838,089
Other non-current assets	134,736	328,006
Total assets	28,849,160	24,887,006
Current liabilities:
Accounts payable	646,649	784,777
Advance from customers	128,321
Other payables and accrued liabilities	942,793	758,907
Income tax payable	1,842,139	1,216,841
Convertible notes, net of discount	7,267,677
Current portion of long-term borrowing	1,268,106	785,456
Total current liabilities	12,095,685	3,545,981
Convertible notes, net of discount		4,488,881
Note payable - related party		13,722
Advance from government grant	37,948	355,754
Long-term borrowing, net of current portion	792,567	628,365
Total liabilities	12,926,200	9,032,703
Commitments and contingencies
EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 13,324,083 issued and outstanding as of December 31, 2012 and December 31, 2011	13,324	13,324
Additional paid-in capital	12,220,181	12,220,181
Retained earnings	2,485,736	2,695,983
Statutory reserve	373,406	373,406
Accumulated other comprehensive income	658,870	551,409
Total Tanke Biosciences Corporation stockholders' equity	15,751,517	15,854,303
Non-controlling interest	171,443
Total Equity	15,922,960	15,854,303
Total Liabilities and Equity	$ 28,849,160	$ 24,887,006